Drugs / CIK cell
Trials 4
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03987867 | Jun 2019 → Jun 2021 | non-small cell lung carcinoma | Tianjin Medical University Cancer Institute and Hospital | Unknown | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT03124498 | Nov 2017 → Jun 2019 | hepatocellular carcinoma | Chuan An Biotechnology Co., Ltd. | Unknown | No outcome recorded |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT01631357 | Dec 2014 → Dec 2018 | non-small cell lung carcinoma, squamous cell carcinoma | Tianjin Medical University Cancer Institute and Hospital | Completed | No outcome recorded |
| Phase not applicable1 trial | ||||||
| — | NCT06389305 | May 2024 → May 2026 overdue | B-cell acute lymphoblastic leukemia | Beijing GoBroad Hospital | Recruiting | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | CIK cell | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03987867 ↗ |
| Known as | CIK | “autologous or allogeneic cytokine-induced killer (CIK) cells” NCT06389305 ↗ |
| Modality | Cell therapy | “CIK cell immunotherapy” NCT01631357 ↗ |
| Route | Intravenous | “CIK cells, 1x10\^10 (10 billion ), intravenous infusion,d14” NCT03987867 ↗ |